U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06992804) titled 'Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease' on March 18.
Brief Summary: The goal of this study is to explore the efficacy and safety of near-infrared light combined with lecanemab in patients with mild Alzheimer's disease (AD).
This study will employ a randomized, double-blind, sham-controlled method with an open-label extension phase. This trial contains the core phase and an extension phase. During the core phase, eligible subjects were selected and randomized (experimental group: control group = 1:1). The subjects who entered the experimental group received treatment with a near-infrared ligh...